ClinicalTrials.Veeva

Menu

A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure (DANUTRIO-HF)

T

Tor Biering-Sørensen

Status and phase

Not yet enrolling
Phase 3

Conditions

Heart Failure

Treatments

Dietary Supplement: Coenzyme Q10 100 Milligrams Oral Capsule
Dietary Supplement: Selenium 100 Micrograms Oral Tablets

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06694727
DANUTRIO-HF

Details and patient eligibility

About

Heart failure is a common and serious condition. Despite rapid advancements in heart failure treatment, the prognosis remains severe. Smaller studies have shown that two simple, safe, and relatively inexpensive nutritional supplements-coenzyme Q10 and selenium-may reduce the risk of complications associated with heart failure. The DANUTRIO-HF trial will investigate whether these supplements can make a difference for individuals with heart failure. The study will assign approximately 4,044 patients from across Denmark to either coenzyme Q10 (100 mg twice daily) or a corresponding placebo, as well as selenium (100 μg twice daily) or its corresponding placebo, and follow how many of them end up being hospitalized for heart failure or dying from heart problems over an estimated two to three-year period.

Full description

This investigator-initiated, pragmatic, registry-based, double-blinded, placebo-controlled, 2x2 factorial, individually randomized trial aims to evaluate the efficacy of daily intake of the nutritional supplements coenzyme Q10 versus placebo, and selenium versus placebo, in preventing heart failure hospitalizations and cardiovascular death in heart failure patients. The trial plans to randomize approximately 4,044 participants in an event-driven design. Participants will be identified through the Danish Administrative Health Registries, which will also serve as the primary source for data collection. Contact with potential participants will be made via the mandatory Danish electronic letter system. No scheduled in-person visits are required in the main study, and all study interventions will be mailed to participants.

A substudy involving up to 600 participants will assess the effects of coenzyme Q10 and selenium on functional capacity, treatment compliance, biochemical biomarkers, and cardiac function and structure. This group will attend two in-person visits for additional evaluations, including echocardiography, blood sampling, and a 6-minute walk test at baseline and at the 1-year follow-up.

Enrollment

4,044 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Individuals aged ≥ 18 years.
  • Registered with a heart failure diagnosis (ICD-10: I50) as a primary discharge diagnosis in The Danish National Patient Registry and at least one claimed prescription of a renin-angiotensin-system inhibitor and a β-blocker within 120 days after HF diagnosis.
  • Informed consent form has been signed and dated.

Exclusion criteria

  • Use of vitamin K-antagonist
  • Registered with a cancer diagnosis (C00-C97 not C44) within the last 5 years excluding cutaneous squamous cell or basal cell carcinoma in The Danish National Patient Registry.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Quadruple Blind

4,044 participants in 4 patient groups, including a placebo group

Coenzyme Q10 intervention, active
Experimental group
Description:
100 mg capsules given twice daily, per oral use
Treatment:
Dietary Supplement: Coenzyme Q10 100 Milligrams Oral Capsule
Coenzyme Q10 intervention, placebo
Placebo Comparator group
Description:
Placebo matching coenzyme Q10
Treatment:
Dietary Supplement: Coenzyme Q10 100 Milligrams Oral Capsule
Selenium intervention, active
Experimental group
Description:
100 μg tables given twice daily, per oral use
Treatment:
Dietary Supplement: Selenium 100 Micrograms Oral Tablets
Selenium intervention, placebo
Placebo Comparator group
Description:
100 μg tables given twice daily, per oral use
Treatment:
Dietary Supplement: Selenium 100 Micrograms Oral Tablets

Trial contacts and locations

1

Loading...

Central trial contact

Tor Biering-Sørensen, MD, MPH, MSc, PhD; Kristoffer G Skaarup, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems